Literature DB >> 526398

Long-term treatment of hypertension with labetalol.

B N Prichard, A J Boakes, R Hernández.   

Abstract

1 Thirty-two hypertensive patients have been treated with labetalol for periods of up to 7 years. 2 Ten patients observed for 6 years from time of stabilization of dosage, did not show any tolerance to labetalol. 3 Postural and exercise hypotension were not seen in these patients over this prolonged follow-up, although they were seen in other patients given over 2 g labetalol daily.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 526398      PMCID: PMC1429736     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

1.  A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

Authors:  G A ROSE; W W HOLLAND; E A CROWLEY
Journal:  Lancet       Date:  1964-02-08       Impact factor: 79.321

2.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

Review 3.  Pharmacological effects of labetalol in man.

Authors:  D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06
  4 in total
  8 in total

Review 1.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

2.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

3.  Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.

Authors:  G R Bellamy; S N Hunyor; D Roffe; J Massang
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

4.  Rapid reduction of blood pressure with acute oral labetalol.

Authors:  A B Davies; V Bala Subramanian; B Gould; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

5.  Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.

Authors:  S Rasmussen; P E Nielsen
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

6.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Labetalol steady-state pharmacokinetics in hypertensive patients.

Authors:  J J McNeil; A E Anderson; W J Louis; K Raymond
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 8.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.